Disse patienter skal monitoreres omhyggeligt for bivirkninger og stigning i viræmi, da sikkerhedsprofilen for efavirenz er forskellig fra proteasehæmmeres sikkerhedsprofil.
These patients should be carefully monitored for rises in viral load and, since the safety profile of efavirenz differs from that of protease inhibitors, for adverse reactions.